Characterization of tau oligomeric seeds in progressive supranuclear palsy

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Gerson, Julia E ^a   Sengupta, Urmi ^a   Lasagna Reeves, Cristian A ^a   Guerrero Muñoz, Marcos J ^a   Troncoso, Juan ^b   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Oligomers; Progressive supranuclear palsy; Seeding; Tau

Indexed keywords

TAU PROTEIN;

CASE CONTROL STUDY; CHEMISTRY; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; METABOLISM; MULTICENTER STUDY; NEUROFIBRILLARY TANGLE; PATHOLOGY; PROGRESSIVE SUPRANUCLEAR PALSY;

CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; MALE; NEUROFIBRILLARY TANGLES; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 84918519815     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-73     Document Type: Article

References (45)

1. Steele JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. Arch Neurol 1964, 10: 333-359. 10.1001/archneur.1964.00460160003001
2. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, Burn DJ: The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001, 124: 1438-1449. 10.1093/brain/124.7.1438
3. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA: Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3: 519-526. 10.1016/0896-6273(89)90210-9
4. Panda D, Goode BL, Feinstein SC, Wilson L: Kinetic stabilization of microtubule dynamics. Biochemistry 1995, 34: 11117-111127. 10.1021/bi00035a017
5. Ingelsson M, Ramasamy K, Russ C, Freeman SH, Orne J, Raju S, Matsui T, Growdon JH, Frosch MP, Ghetti B, Brown RH, Irizarry MC, Hyman BT: Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol 2007, 114: 471-479. 10.1007/s00401-007-0280-z
6. Sergeant N, Wattez A, Delacourte A: Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neurochem 1999, 72: 1243-1249. 10.1046/j.1471-4159.1999.0721243.x
7. Arai T, Ikeda K, Akiyama H, Tsuchiya K, Yagishita S, Takamatsu J: Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy. Clin Med 2001, 12: 935-938.
8. Arai T, Ikeda K, Akiyama H, Nonaka T, Hasegawa M, Ishiguro K, Iritani S, Tsuchiya K, Iseki E, Yagishita S, Oda T, Mochizuki A: Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004, 55: 72-79. 10.1002/ana.10793
9. Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y: Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their isoform distribution and phosphorylation. Ann Neurol 1998, 43: 193-204. 10.1002/ana.410430209
10. Arai T, Ikeda K, Akiyama H, Tsuchiya K, Iritani S, Ishiguro K, Yagishita S, Oda T, Odawara T, Iseki E: Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2003, 105: 489-498.
11. Yamada T, McGeer PL, McGeer EG: Appearance of paired nucleated, tau-positive glia in patients with progressive supranuclear palsy brain tissue. Neurosci Lett 1992, 135: 99-102. 10.1016/0304-3940(92)90145-W
12. Hauw JJ, Verny M, Delaère P, Cervera P, He Y, Duyckaerts C: Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett 1990, 119: 182-186. 10.1016/0304-3940(90)90829-X
13. Arima K: Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 2006, 26: 475-483. 10.1111/j.1440-1789.2006.00669.x
14. Hof PR, Delacourte A, Bouras C: Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: a quantitative analysis of six cases. Acta Neuropathol 1992, 84: 45-51. 10.1007/BF00427214
15. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R: Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 2011, 6: 1-14. 10.1186/1750-1326-6-1
16. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R: Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J 2012, 26: 1946-1959. 10.1096/fj.11-199851
17. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R: Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2012, 2: 700.
18. Gerson JE, Kayed R: Formation and propagation of tau oligomeric seeds. Front Neurol 2013., 4: doi:10.3389/fneur.2013.00093
19. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A: Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 2006, 54: 197-201. 10.1016/j.neures.2005.11.009
20. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A: Granular tau oligomers as intermediates of tau filaments. Biochemistry 2007, 46: 3856-3861. 10.1021/bi061359o
21. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI: Characterization of prefibrillar tau oligomers in vitro and in Alzheimers disease. J Biol Chem 2011, 286: 23063-23076. 10.1074/jbc. M111.237974
22. Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT: The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012, 181: 1426-1435. 10.1016/j.ajpath.2012.06.033
23. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, Koffie RM, Frosch MP, Hyman BT, Spires-Jones TL: Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol 2011, 179: 2071-2082. 10.1016/j.ajpath.2011.07.004
24. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C: Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27: 3650-3662. 10.1523/JNEUROSCI.0587-07.2007
25. Polydoro M, Acker CM, DuffK, Castillo PE, Davies P: Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009, 29: 10741-10749. 10.1523/JNEUROSCI.1065-09.2009
26. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH: Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309: 476-481. 10.1126/science.1113694
27. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53: 337-351. 10.1016/j.neuron.2007.01.010
28. Sahara N, DeTure M, Ren Y, Ebrahim AS, Kang D, Knight J, Volbracht C, Pedersen JT, Dickson DW, Yen SH, Lewis J: Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis 2013, 33: 249-263.
29. Golbe LI: The tau of PSP: a long road to treatment. Mov Disord 2014, 29: 431-434. 10.1002/mds.25855
30. Lasagna-Reeves CA, Glabe CG, Kayed R: Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem 2011, 286: 22122-22130. 10.1074/jbc. M111.236257
31. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muñoz MJ, Jackson GR, Kayed R: Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010, 49: 10039-10041. 10.1021/bi1016233
32. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997, 41: 17-24. 10.1002/ana.410410106
33. Vogt BA, Vogt LJ, Vrana KE, Gioia L, Meadows RS, Challa VR, Hof PR, Van Hoesen GW: Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease. Exp Neurol 1998, 153: 8-22. 10.1006/exnr.1998.6852
34. Terry RD: Do neuronal inclusions kill the cell? J Neural Transm Suppl 2000, 59: 91-93.
35. van de Nes JA, Nafe R, Schlote W: Non-tau based neuronal degeneration in Alzheimer's disease - an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res 2008, 1213: 152-165.
36. Lasagna-Reeves C, Sengupta U, Castillo-Carranza D, Gerson J, Guerrero-Munoz M, Troncoso J, Jackson G, Kayed R: The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun 2014, 2: 56. 10.1186/2051-5960-2-56
37. Alonso ADC, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K: Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 2001, 276: 37967-37973.
38. Alonso ADC, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K: Hyperphosphorylation induces self-assembly of into tangles of paired helical filaments/straight filaments. PNAS 2001, 98: 6923-6928. 10.1073/pnas.121119298
39. Pérez M, Cuadros R, Smith MA, Perry G, Avila J: Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett 2000, 486: 270-274. 10.1016/S0014-5793(00)02323-1
40. Greenwood JA, Johnson GVW: Localization and in situ phosphorylation state of nuclear tau. Exp Cell Res 1995, 220: 332-337. 10.1006/excr.1995.1323
41. Díaz-Hernández M, Gómez-Ramos A, Rubio A, Gómez-Villafuertes R, Naranjo JR, Miras-Portugal MT, Avila J: Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem 2010, 285: 32539-32548. 10.1074/jbc. M110.145003
42. Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP: Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 2013, 14: 389-394. 10.1038/embor.2013.15
43. Keith-Rokosh J, Ang LC: Progressive supranuclear palsy: a review of co-existing neurodegeneration. Can J Neurol Sci 2008, 35: 602-608.
44. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Kayed R: Specific targeting of tau oligomers in htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis 40: S97-S111.
45. Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett ADT, Dineley KT, Jackson GR, Kayed R: Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 2014, 34: 4260-4272. 10.1523/JNEUROSCI.3192-13.2014